We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Stents and Angioplasty Reduce Mortality by 50%

By HospiMedica staff writers
Posted on 17 May 2006
A new study suggests that the use of stents in reperfusion therapy after a heart attack and angioplasty is associated with a 50% reduction in mortality, compared to balloon angioplasty alone.

Researchers at the State University of New York Stony Brook School of Medicine (NY, USA) retrospectively examined data on more than 6,000 patients who, between 1998 and 1999, presented within 23 hours of acute MI and underwent percutaneous coronary intervention. More...
Stents were placed in 87% of patients. Those who received stents were younger (61 versus 62 years) and were more likely to be male (33% versus 29%). They were all less likely to have had a history of hypertension and diabetes and to have a creatinine level of 2.5 mg/dl or beyond (0.8% versus 2.0%).

Stent use was associated with a significant reduction in length of stay (5.9 versus 8.1 days), major cardiovascular events (4.1% versus 12%), and in-hospital mortality (3.5% versus 9.3%). After adjustment, stent use was associated with a 50% decrease in the risk of in-hospital mortality compared to balloon angioplasty alone. The researchers noted that although drug-eluting stents were not studied, this should not have affected these short-term findings. The study's findings were published in the April 1, 2006, issue of the American Journal of Cardiology.

"All patients who present with an acute heart attack should receive a stent rather than balloon angioplasty alone, said senior investigator Dr. David L. Brown. "Treatment with a stent reduced the risk of dying in the hospital by 50%.”



Related Links:
Stony Brook School of Medicine

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.